IGC Pharma Inc (IGC) — Titan Protect Analysis

IGC

IGC Pharma Inc

Healthcare · ·

$0.29

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$30M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-3.52

Based on estimated future earnings — lower means cheaper

Rev Growth

-3.9%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-83.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$4.13

+1322% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 2 analysts covering this stock

About IGC Pharma Inc

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MI

https://igcpharma.com

Country: United States Employees: 70 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

-0.049

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.3318

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.395

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-21.6%

Historical annualised return based on price data

Max Drawdown

-54.6%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

100

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.50

Less volatile than the market — more defensive

52W High

$0.50

42% below the year high

52W Low

$0.24

21% above the year low

Avg Volume

1,146,466

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.6

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.06

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

14.98

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

46.2%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-775.4%

Profit from core operations before interest and tax

Free Cash Flow

$-2,521,375

Negative — the business is spending more than it generates

Revenue (TTM)

$1M

Total revenue over the last 12 months

Net Income

$-6,446,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$5.25

Target Median

$4.13

Target Low

$3.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go